Pharmacognosy intro
Citrus bergamia Risso and Poit., Rutaceae. Cold-pressed essential oil from fruit rind. Hybrid of bitter orange (C. aurantium) and sweet lime (C. limetta), cultivated almost exclusively in Calabria, Italy. Italian Pharmacopoeia; ISO 3520; FDA GRAS for flavoring. Essential oil: limonene (25-53%), linalyl acetate (15-40%), linalool (2-20%), gamma-terpinene, beta-pinene, geraniol. Furanocoumarins (bergamottin, 5-MOP) present in standard oil, removed in bergaptene-free (FCF) preparations. Combined linalool and linalyl acetate can reach 60% of total composition. Bergamot's anxiolytic mechanism is multi-layered. Linalool positively modulates GABAA benzodiazepine sites, enhancing chloride conductance without direct activation, producing anxiolysis without sedation or dependence risk. Oil components also interact with 5-HT1A receptors (the buspirone target), providing an independent mood-elevating pathway. A third mechanism involves metabotropic glutamate receptor (mGluR2/3, mGluR5) modulation, novel among essential oils. Rombola et al. (2017) identified modulation of amino acid neurotransmitter release (aspartate, glycine, taurine, GABA) in hippocampal synaptosomes, establishing a polypharmacological profile beyond classical GABA/serotonin pathways. Evidence suggests dopaminergic facilitation in the nucleus accumbens. Watanabe et al. (2015, n=41) found 15 minutes of inhalation significantly reduced salivary cortisol and shifted autonomic balance toward parasympathetic dominance. Han et al. (2017, n=57) documented 17% increase in positive feelings from bergamot diffusion. Perna et al. (2019, 31 studies, n=1,709) reviewed efficacy for cardiovascular, dermatological, mood, and anxiety outcomes. Navarra et al. (2015) positioned bergamot as the most pharmacologically complex anxiolytic essential oil. EEG shows increased alpha-wave activity (relaxed alertness), distinct from beta or theta patterns. Primary safety concern: phototoxicity. Bergamottin causes severe burns (berloque dermatitis) with UV exposure up to 18 hours after topical application. FCF oil eliminates this risk. Maximum dermal use: standard 0.4%, FCF unrestricted. Bergamottin potently inhibits CYP3A4, clinically significant with oral consumption affecting statins, calcium channel blockers, and immunosuppressants.